echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The vaccine industry has gradually improved, with three leading enterprises recommended

    The vaccine industry has gradually improved, with three leading enterprises recommended

    • Last Update: 2020-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] since the second half of 2019, with the promulgation of vaccine management law on December 1, 2019, the threshold of industry production has been raised, and with the release of technical guidelines for vaccine clinical comparability research, the threshold of vaccine research and development may be further improved It can be seen that in the future, the pattern of vaccine industry will continue to be optimized and the industry will gradually improve Relevant securities personage said that they are still optimistic about the leading enterprises with strict production control and outstanding R & D strength, and mainly recommend Kangtai biology, Zhifei biology and Changchun hi tech The 23 valent pneumococcal polysaccharide vaccine of Beijing minhai Biotechnology Co., Ltd under Kangtai bio, was approved for marketing in 2018 On December 9, 2019, Kangtai biology released a notice that the application for new drug production registration of 13 valent pneumococcal conjugate vaccine developed by the wholly-owned subsidiary Beijing minhai Biotechnology Co., Ltd has been accepted by the State Food and drug administration The industry expects that Kangtai bio's product is expected to be approved for listing in 2020, and will contribute a large amount of incremental performance since 2021, sharing a market share of more than 7 billion yuan The original 13 price pneumonia vaccine was developed by Pfizer, which is the only one producing and selling the vaccine In 2018, Pfizer's global sales volume of the vaccine was about 5.8 billion US dollars, and its total output value in China was about 2.686 billion yuan On the other hand, Watson bio's heavyweight product, 13 price pneumonia vaccine, has also been approved for marketing, and is expected to bring more than 1 billion yuan in profits Because, in the future, Watson biology, Kangtai biology and Pfizer will share the domestic market space Zhifei biological Zhifei biological is developed in the mode of "independent + agent", with a rich product line At present, there are 10 vaccine varieties on sale, including the agent's four and nine price vaccines In recent years, Zhifei's performance has maintained a rapid growth In 2018, the total revenue and net profit were 5.228 billion yuan and 1.451 billion yuan respectively, with year-on-year growth of 289.64% and 235.20% respectively In the first three quarters of 2019, the company's total revenue reached 7.666 billion yuan, a year-on-year increase of 119.35%; the net profit attributable to the parent company was 1.763 billion yuan, a year-on-year increase of 62.25% In addition, there are many vaccine products under development in Zhifei biology For example, the tetravalent influenza vaccine and the 23valent pneumonia polysaccharide vaccine have entered the phase III clinical stage, and the lyophilized human rabies vaccine (MRC-5 cell) is also in the phase III clinical stage These are also the new performance growth points of the company in the future However, the industry also pointed out that the gross profit margin of Zhifei biology is relatively low, and the profit space is seriously compressed In the future, it is necessary to change the product structure from the existing mode of agent products to the mode of independent products At the same time, we need to work hard in R & D management to see better R & D results In the evening of December 12, 2019, Changchun hi tech announced that in view of the fact that the approval documents for the production of nasal spray attenuated influenza vaccine are in the approval stage of the State Drug Administration and the characteristics of seasonal sales of influenza vaccine, it is decided to establish the production base I of Baike biological vaccine The production time of nasal attenuated influenza vaccine in the project is postponed to June 2020, and the production time of new rabies vaccine and new DPT combined vaccine is expected to remain unchanged It is reported that the production time of Changchun hi tech's new rabies vaccine was postponed to December 2020, and the production time of the new DPT combined vaccine was postponed to December 2022 With the production of these vaccines, it may become the driving force of Changchun hi tech's performance growth In addition, the industry believes that Changchun hi tech's freeze-dried live attenuated varicella vaccine and human rabies vaccine also have potential competitive advantages in the vaccine industry.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.